Helus Pharma, based in Vancouver, BC, announced on February 26, 2026, the groundbreaking development that the first psilocybin compound has successfully obtained two positive Phase 3 results for treating treatment-resistant depression. This significant achievement could mark a transformative change in the approach to managing depression. This breakthrough holds the promise of offering a new treatment option for patients struggling with depression.